Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
See our latest analysis for Vertex Pharmaceuticals. Those CASGEVY and kidney disease updates are landing against a strong backdrop, with the share price at $460.31 after a roughly 21 percent 3 month share price return and a near 99 percent 5 year total shareholder return. This suggests momentum is still building rather than fading. If this kind of pipeline driven story appeals to you, it could be worth exploring other healthcare names using our healthcare stocks to spot similar opportunities. With shares already near analyst targets and long term returns approaching 100 percent, investors face a tougher call: is Vertex still trading below its intrinsic potential, or is the market already pricing in the next growth wave? With Vertex closing at $460.31 versus a narrative fair value near $485, the current setup implies modest upside if the long term thesis delivers. Commercial success and broad payer coverage for recent launches, particularly JOURNAVX and CASGEVY, are setting
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12Business Wire
- From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes DiabetesGlobeNewswire
- How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review [Yahoo! Finance]Yahoo! Finance
- Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025? [Yahoo! Finance]Yahoo! Finance
- Sharp Rise in Senior Overdose Deaths Drives Launch of New Healthy Aging Video Program [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/3/25 - Beat
VRTX
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- VRTX's page on the SEC website